Nuclear receptor related 1 (Nurr1) is a promising target for neuroprotection in diseases like Parkinson’s and Alzheimer’s, yet its activation mechanism by synthetic ligands remains unclear. Here, the authors elucidate Nurr1’s activation by vidofludimus, revealing its allosteric binding site and developing a more potent Nurr1 agonist, advancing rational drug design.
- Úrsula López-García
- Jan Vietor
- Daniel Merk
